ECOR electroCore

electroCore, Inc. to Present at Little Grapevine’s G1 Microcap Virtual Conference

electroCore, Inc. to Present at Little Grapevine’s G1 Microcap Virtual Conference

BASKING RIDGE, N.J., May 29, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that that a prerecorded virtual presentation featuring Dan Goldberger, Chief Executive Officer, will be available at Little Grapevine™ () beginning today, May 29, 2020, at 10:30 a.m. Eastern Standard Time.

Accompanying the presentation will be a short executive introduction, as well as a brief Q&A with Mr. Goldberger. A copy of the slides will be available at  and under the Investor Relations section of electroCore’s website: .

No fee is required to join or view the company’s Little Grapevine Conference presentation, as it is open to the public.

Register at to be notified when the event is about to begin.

About Little Grapevine

Little Grapevine is a web-based platform that invites companies to participate in on-line virtual conferences with video presentations, video interviews, podcasts and more. Content is available for free for the public and conveniently archived and categorized on littlegrapevine.com, which serves as an all-in-one tool for investors seeking to research companies in the microcap space. At the end of each presentation, featured companies also answer Little Grapevine’s questions about their business. For more information about Little Grapevine, please visit .

About electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s initial targets are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit .

Investors:

Hans Vitzthum

LifeSci Advisors

617-430-7578

or

Media Contact:

Jackie Dorsky

electroCore

973-290-0097

EN
29/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on electroCore

 PRESS RELEASE

electroCore Names Kelly Benning, Accomplished Healthcare Executive, as...

electroCore Names Kelly Benning, Accomplished Healthcare Executive, as SVP of Truvaga ROCKAWAY, N.J., Aug. 12, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Kelly Benning has been hired as the Senior Vice President of Truvaga, effective July 21, 2025. Ms. Benning, who brings almost three decades of leadership experience across digital health, AI-enabled technologies, and consumer wellness, will lead electroCore’s consumer wellness division. Kelly Benning, electroCore's Senior Vice Preside...

 PRESS RELEASE

electroCore Announces Second Quarter 2025 Financial Results

electroCore Announces Second Quarter 2025 Financial Results Net sales of $7.4 million increased 20% vs. Q2’2024; YTD net sales of $14.1 million increased 22% vs. first half of 2024 Cash, cash equivalents, restricted cash, and marketable securities of $7.4 million as of June 30, 2025  Company to host a conference call and webcast today, August 6, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic technology company, today announced financial results for the three and...

 PRESS RELEASE

electroCore Appoints James C. Theofilos to the Board of Directors

electroCore Appoints James C. Theofilos to the Board of Directors ROCKAWAY, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that James C. Theofilos has been appointed to the Board of Directors, effective August 1, 2025. “I’m honored to have been appointed to the Board of Directors at electroCore,” said Mr. Theofilos. “For nearly two decades, the Theofilos family has deeply believed in the power of the vagus nerve and proudly supported electroCore as both an early investor and found...

 PRESS RELEASE

electroCore to Announce Second Quarter June 30, 2025 Financial Results...

electroCore to Announce Second Quarter June 30, 2025 Financial Results on Wednesday, August 6, 2025 ROCKAWAY, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the second quarter ended June 30, 2025, after the close of the market on Wednesday, August 6, 2025. Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below: Wednesday, August 6, 4:30 PM ...

 PRESS RELEASE

electroCore to Participate in Upcoming Investor Conferences

electroCore to Participate in Upcoming Investor Conferences ROCKAWAY, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor conferences. Needham 10th Annual Virtual MedTech and Diagnostics Conference, taking place virtually on Monday, August 11 and Tuesday, August 12, 2025. Management will host will host one-on-one meetings throughout both days. Canaccord Genuity 45th Annual Growth Conference, taking place in Massachusetts on Tues...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch